Analysts Set LifeMD, Inc. (NASDAQ:LFMD) Target Price at $12.00

LifeMD, Inc. (NASDAQ:LFMD) has received a consensus rating of “Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have covered the stock in the last year is $12.00.

Several research analysts recently issued reports on LFMD shares. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. B. Riley started coverage on shares of LifeMD in a research note on Friday, August 23rd. They set a “buy” rating and a $11.00 target price on the stock. Finally, KeyCorp cut their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LFMD. Vanguard Group Inc. lifted its stake in shares of LifeMD by 12.5% in the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after buying an additional 128,701 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of LifeMD by 852.6% in the third quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after buying an additional 108,822 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of LifeMD by 63.6% during the second quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after purchasing an additional 91,183 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of LifeMD by 261.8% during the first quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock valued at $1,198,000 after purchasing an additional 84,413 shares in the last quarter. Finally, X Square Capital LLC bought a new position in shares of LifeMD during the second quarter valued at about $509,000. 35.52% of the stock is owned by institutional investors.

LifeMD Trading Up 1.4 %

LFMD opened at $4.38 on Friday. LifeMD has a twelve month low of $3.99 and a twelve month high of $12.88. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83. The company has a fifty day moving average of $4.83 and a 200-day moving average of $6.67. The stock has a market cap of $188.64 million, a PE ratio of -6.26 and a beta of 1.23.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million for the quarter, compared to the consensus estimate of $48.47 million. During the same period in the previous year, the business posted ($0.23) EPS. On average, sell-side analysts predict that LifeMD will post -0.49 EPS for the current year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.